HPV Cotesting: Age to Start and Management of Positive Results
For average-risk women, HPV and Pap cotesting should begin at age 30 years and be repeated every 5 years; if HPV is positive with negative cytology, repeat cotesting at 1 year is recommended.
Age to Initiate Cotesting
Cotesting is recommended only for women aged 30-65 years 1, 2, 3. The most recent ACS guidelines (2020) actually shift away from cotesting as the preferred strategy, now recommending primary HPV testing alone every 5 years starting at age 25, but cotesting every 5 years remains an acceptable alternative where primary HPV testing is unavailable 4.
For women aged 21-29 years:
- Do NOT perform cotesting 1, 2
- Use cytology alone every 3 years
- HPV testing in this age group leads to unnecessary interventions for transient infections that will clear spontaneously 5
The rationale for waiting until age 30 is that HPV infections are extremely common in younger women but typically transient, while persistent infections (more common after age 30) carry the actual cancer risk 5.
Management When HPV is Positive
HPV Positive with Negative Cytology
The critical management depends on whether HPV 16/18 genotyping is performed:
If HPV 16 or 18 detected: Proceed directly to colposcopy 5
- These high-risk genotypes confer sufficient CIN3+ risk even with negative cytology to warrant immediate evaluation
If other high-risk HPV types (non-16/18): Repeat cotesting in 1 year 6
- At 1-year follow-up, approximately 45% will have cleared the HPV infection 6
- If HPV negative at 1 year, return to routine screening
- If HPV positive or any cytologic abnormality at 1 year, proceed to colposcopy
HPV Positive with Abnormal Cytology
- ASC-US or worse with positive HPV: Proceed to colposcopy 5
- HPV genotyping for 16/18 does not change management when cytology is already abnormal 5
Important Caveats
Common pitfall: The 2014 ASCCP guidelines initially suggested 5-year follow-up for HPV-negative ASC-US, but this was revised to 3-year cotesting after larger cohort data showed higher cancer risk than initially estimated 5.
Screening cessation: Women reaching age 65 with HPV-negative ASC-US should continue screening with cotesting at 3 years until achieving 2 consecutive negative cotests or 3 consecutive negative Pap tests 5. The cancer risk in this scenario is disproportionately high despite low dysplasia risk.
Transition note: The 2020 ACS guidelines 4 represent a shift toward primary HPV testing as preferred over cotesting, though cotesting remains acceptable during this transitional period. The USPSTF 2018 guidelines 7 similarly endorse either strategy for women 30-65 years.